In 273,770 US patients with established ASCVD, rising lipoprotein(a) (nmol/L) was steadily associated with higher risk of recurrent events; the excess risk was partially blunted in those receiving high‑impact LDL‑lowering therapy, most notably PCSK9 inhibitors.